Evaluation of the Safety, Efficacy, and Pharmacokinetics of Intravenous Deferiprone in HIV-Positive Subjects

Inclusion Criteria: * HIV-1 positive * HIV treatment-naïve: no previous treatment with a combination anti-retroviral therapy (cART) or highly active anti-retroviral therapy (HAART) regimen * HIV-1 RNA \> 10,000 copies/mL * ALT or AST ≤ 2.0 x upper limit of normal range, and bilirubin within normal range * Body mass index (BMI) of 18.5 to 30.0 kg/m\^2 * Absolute neutrophil count at baseline of ≥1.0 x 10\^9/L (black African population only) or ≥1.5 x 10\^9/L (all other races) Exclusion Criteria: * Evidence of AIDS-associated illness, excluding superficial candidiasis * CD4+ T-cell count of \< 350/mm\^3 * Positive for active or latent tuberculosis, as determined by the QuantiFERON®-TB Gold test * Active, serious infections (other than HIV-1 infection) within the 30 days prior to screening * Positive for hepatitis B surface antigen (HBsAg) and/or hepatitis virus C (HCV) antibodies * History or presence of malignancy * A serious, unstable chronic illness during the past 3 months before screening * A serious, unresolved acute illness at screening